Seelos therapeutics, inc. (APRI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues
Grant revenue

375

0

-

-

-

-

-

-

-

-

-

Total revenues

375

0

-

-

-

-

-

-

-

-

-

License fee revenue

-

-

-

-

3,600

8,454

941

4,276

877

40

2,681

Royalty revenue

-

-

-

-

650

36

0

0

-

-

-

Grant revenue

-

-

-

-

-

-

-

-

483

-

-

Product sales

-

-

-

-

589

769

21

23

0

527

10

Contract service revenue

-

-

-

-

-

0

1,549

3,646

2,243

4,406

281

Total revenue

-

-

-

-

4,839

9,259

2,511

7,945

3,603

4,973

2,973

Cost of goods sold

-

-

-

-

922

918

23

10

0

386

4

Cost of Sandoz rights

-

-

-

-

0

0

2,608

4,230

1,858

3,557

123

Gross profit

-

-

-

-

3,917

8,341

-120

3,705

1,745

1,030

2,845

Operating expense
Research and development

22,563

553

3,463

5,880

14,649

21,288

5,123

5,375

5,821

2,110

1,883

General and administrative

7,559

2,631

7,210

7,778

10,516

11,418

13,554

15,336

11,451

10,153

4,196

Gain on contract settlement

-

-

-

-

-

900

534

0

0

-

-

Recovery loss on sale of subsidiary

-

-

-

-

-

50

255

250

-2,760

-

-

Deconsolidation of former French Subsidiaries

-

-

-

-

-

846

641

0

0

-

-

Loss on disposal of assets

-

-

-2

-14

-102

0

0

-

-

-

-

Impairment on goodwill and intangible assets

-

-

-

-

-

-

-

8,254

0

10,168

-

Acquisiton costs

-

-

-

-

-

-

-

-

-

-

585

Total operating expense

30,122

3,184

10,675

13,672

25,267

30,900

17,247

28,715

20,032

22,431

6,665

Loss before other expense

-29,747

-3,184

-10,675

-13,672

-21,350

-22,559

-17,367

-25,010

-18,287

-21,401

-3,819

Other income (expense)
Interest income

151

0

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

25

Interest expense

29

131

-

-

-

-

-

-

-

-

28,696

Interest expense

-

-

-83

-983

-895

-339

-727

-325

-364

-8,822

-

Loss on warrant issuance

5,020

0

0

461

0

-

-

-

-

-

-

Gain on sale of investment

-

-

-

-

-

0

2,600

0

0

-

-

Change in fair value of warrant liabilities

16,501

0

646

-7,479

-3,236

0

0

-

-

-

-

Change in fair value of convertible notes payable

-109

-160

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-422

0

-

-82

0

0

-

-

-

Rental income

-

-

-

-

-

-

-

-

-

415

-

Other income, net

-

-

77

-22

-14

503

-376

175

426

300

10

Total other income (expense)

-21,508

-291

-1,074

6,013

2,327

82

1,497

-150

62

-8,107

-28,660

Loss from continuing operations

-

-

-11,749

-7,659

-

-22,477

-15,870

-25,676

-18,225

-29,508

-

(Loss) income from discontinued operations

-

-

12,070

226

-

-

-

-

-

-

-

Loss from continuing operations before income tax expense

-

-

-

-

-

-

-

-25,160

-18,225

-

-

Loss from continuing operations before income taxes

-

-

-

-

-

-

-

-

-

-29,508

-32,480

Income tax expense

-

-

-

-

-

-

-

516

0

-

-437

Income (loss) from discontinued operations

-

-

-

-

-

691

-1,068

-6,095

108

-

-

Net loss and comprehensive loss

-51,255

-3,475

321

-7,433

-19,023

-21,786

-16,938

-31,771

-18,117

-29,508

-32,042

Continuing operations (in usd per share)

-

-

-29.64

-1.18

-

-0.57

-0.46

-0.94

-0.91

-2.49

-

Discontinued operations (in usd per share)

-

-

30.45

-

-

-

-

-

-

-

-

Discontinued operations (USD per share)

-

-

-

0.03

-

0.02

-0.03

-0.22

0.01

-

-

Net loss per share basic and diluted

-2.52

-1.13

0.81

-1.15

-3.83

-0.55

-0.49

-1.16

-0.90

-2.49

-5.43

Weighted average common shares outstanding basic and diluted loss

20,308

3,081

396

6,517

4,972

39,540

34,413

27,458

20,023

11,847,703

-

Net loss

-51,255

-3,475

321

-7,433

-

-

-

-31,771

-18,117

-29,508

-32,042

Foreign currency translation adjustments

-

-

-

-

-

-

-

641

0

-

-

Comprehensive loss

-

-

-

-

-

-

-

-31,130

-18,117

-29,508

-

Weighted average common shares outstanding used for basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

5,906